We are seeking volunteers for the SURPASS-4 study which is a clinical trial investigating the safety and effectiveness of tirzepatide when taken once weekly compared to insulin taken once daily in people with type 2 diabetes and increased cardiovascular risk.
The primary purpose of the study aims to address the following questions:
- Whether tirzepatide can help study participants with type 2 diabetes
- The safety of tirzepatide and any side effects when taken
- How much tirzepatide should be given to study participants
- How tirzepatide compares to insulin glargine
We are seeking people with a condition, Diabetic Kidney Disease (DKD), to participate in a study. The study is testing a new way of treating DKD with an drug called "propagermanium".
Propagermanium is an experimental treatment in Australia. This means it has not been approved by the Therapeutic Goods Administration for treatment of DKD in Australia however it has been licensed for use in Japan since 1994 for the treatment of chronic hepatitis B infection.
The purpose of this trial is to test if propagermanium is safe and effective in treating participants with DKD who are on a daily dose of 300 mg irbesartan when compared to placebo.
This study will determine how safe and effective the drug is by:
- monitoring symptoms that you may experience while on the study;
- measuring levels of albuminuria and your kidney function during the course of the study;
- measuring the levels of propagermanium and irbesartan that enters your blood and urine.